By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Hydroxamic Acids. According to news originating from Milan, Italy, by NewsRx correspondents, research stated, "To describe macular lesions in patients with deferoxamine (DFO) retinopathy, and to follow their clinical course using multimodal imaging. The authors retrospectively reviewed charts and multimodal imaging of 20 patients with beta-thalassemia diagnosed with DFO retinopathy (40 eyes) after a minimum of 10 years of DFO treatment."
Our news journalists obtained a quote from the research from the University of Milan, "Imaging included fundus photography, near-infrared reflectance and fundus autofluorescence imaging on confocal laser scanning ophthalmoscope, and spectral domain optical coherence tomography. Mean age of the 20 patients was 45 years, and mean duration of subcutaneous DFO therapy was 32 years (range, 20-52 years). Ten patients (50%) showed different types of pattern dystrophy-like fundus changes, including butterfly shaped-like (n = 3), fundus flavimaculatus-like (n = 3), fundus pulverulentus-like (n = 3), and vitelliform-like (n = 1) changes. Ten patients (50%) presented only minimal changes in the macula; these patients were significantly younger than patients presenting other patterns (P = 0.023). Confocal laser scanning ophthalmoscope and spectral domain optical coherence tomography showed that these abnormalities were more diverse and widespread than expected by ophthalmoscopy. Abnormal fundus autofluorescence and/or near-infrared reflectance signals corresponded to accumulation of material located within the outer retina or in the Bruch membrane-retinal pigment epithelium (RPE) complex on spectral domain optical coherence tomography. Follow-up examinations during a 40-month period revealed progressive development of RPE atrophy in areas of pattern dystrophy-like changes. DFO retinopathy included a variety of pattern dystrophy-like changes or minimal changes affecting the RPE-Bruch membrane-photoreceptor complex. Multimodal imaging demonstrated that fundus changes were more diverse and widespread than expected from ophthalmoscopy."
According to the news editors, the research concluded: "Consistently with previous histologic description of DFO retinopathy, multimodal imaging confirmed that photoreceptor outer-derived retinoids, various fluorophores, and RPE displacement or clumping are involved in DFO retinopathy, finally leading to frank RPE atrophy in most cases of pattern dystrophy-like changes."
For more information on this research see: Multimodal Imaging In Deferoxamine Retinopathy. Retina-The Journal of Retinal and Vitreous Diseases, 2014;34(7):1428-1438. Retina-The Journal of Retinal and Vitreous Diseases can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Hydroxamic Acids).
The news correspondents report that additional information may be obtained from F. Viola, University of Milan, Ca Granda Fdn Osped Maggiore Policinico, Dept. of Clin Sci & Community Hlth, Ophthalmol Unit, I-20122 Milan, Italy. Additional authors for this research include G. Barteselli, L. Dell'Arti, D. Vezzola, C. Mapelli, E. Villani and R. Ratiglia.
Keywords for this news article include: Milan, Italy, Europe, Deferoxamine, Hydroxamic Acids, Imaging Technology, Optical Coherence Tomography
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC